Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada



    TORONTO, April 11 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a
wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today
that Ranbaxy has received approval to manufacture and market RAN(TM)-Cefprozil
Tablets, 250mg and 500mg, and RAN(TM)-Cefprozil  Powder for Oral Suspension,
250mg/5mL from Health Canada.  The total market size for Cefzil(TM)(*) in Canada
was CAD 28.2 million dollars (IMS-MAT: Dec 2006).
    Cefprozil Tablets and Powder for Oral Suspension are indicated for the
treatment of upper respiratory tract infections, uncomplicated skin and
urinary tract infections.
    "We are pleased to receive these approvals for RAN(TM)-Cefprozil, Tablets
and Powder for Oral Suspension to expand the number of product offerings that
Ranbaxy commercializes for use by patients who require the therapeutic
benefits of this product where indicated.  This further adds to our expanding
generic product portfolio which will have benefits of offering an affordable
generic alternative to the brand that will now be accessible to all
Canadians," according to Bill Abboud, President, RPCI.

    Ranbaxy Pharmaceuticals Canada Inc., (RPCI) based in Mississauga,
Ontario, Canada, is a wholly subsidiary of Ranbaxy Laboratories Limited (RLL),
India's largest pharmaceutical company.  RPCI is engaged in the sale and
distribution of generic prescription products in the Canadian healthcare
system.

    Ranbaxy Laboratories Limited, headquartered in India, is an integrated,
research based, international pharmaceutical company producing a wide range of
quality, affordable generic medicines, trusted by healthcare professionals and
patients across geographies. Ranbaxy's continued focus on R&D has resulted in
several approvals in developed markets and significant progress in New Drug
Discovery Research. The Company's foray into Novel Drug Delivery Systems has
led to proprietary "platform technologies", resulting in a number of products
under development.  The Company is serving its customers in over 125 countries
and has an expanding international portfolio of affiliates, joint ventures and
alliances, ground operations in 49 countries and manufacturing operations in 9
countries.

    (*)Cefzil(TM), Bristol-Myers Squibb Canada Inc., Canada

    
    Contacts:  Charles M. Caprariello                     Edwige Buteau
               Vice President, Corporate Communications   RF Binder Partners
               Ranbaxy Inc.                               (212) 994-7517
               (609) 720-5615

               Bill Abboud                                Anuj Baveja
               President and General Manager              RF Binder Partners
               Ranbaxy Pharmaceuticals Canada, Inc.       (212) 994-7552
               (905) 219-8820

    




For further information:

For further information: Charles M. Caprariello, Vice President,
Corporate Communications, Ranbaxy Inc., +1-609-720-5615; or Bill Abboud,
President and General Manager, Ranbaxy Pharmaceuticals Canada, Inc.,
+1-905-219-8820; or Edwige Buteau, +1-212-994-7517, or Anuj Baveja,
+1-212-994-7552, both of RF Binder Partners; Web Site: http://www.ranbaxy.com

Organization Profile

RANBAXY PHARMACEUTICALS CANADA, INC.

More on this organization

RANBAXY LABORATORIES LIMITED

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890